Inhibitory effects of Chelidonium majus extract on atopic dermatitis-like skin lesions in NC/Nga mice

J Ethnopharmacol. 2011 Nov 18;138(2):398-403. doi: 10.1016/j.jep.2011.09.028. Epub 2011 Sep 22.

Abstract

Aim of the study: Chelidonium majus (CM) has traditionally been used for treatment of various inflammatory diseases including atopic dermatitis (AD). However its action on atopic dermatitis (AD) is unclear. Therefore, we investigated the effect of CM on AD using NC/Nga mice as an AD model.

Materials and methods: The effect of CM on 1-chloro-2,4-dinitrobenzene (DNCB) induced NC/Nga mice was evaluated by examining skin symptom severity, itching behavior, ear thickness, levels of serum immunoglobulin E (IgE), tumor necrosis factor-α (TNF-α), and interlukin-4 (IL-4), skin histology.

Results: The CM significantly reduced the total clinical severity score, itching behavior, ear thickness and the level of serum IgE in AD mouse model. CM not only decreased TNF-α but also IL-4.

Conclusion: These results suggest that CM may be a potential therapeutic modality for AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chelidonium / chemistry*
  • Dermatitis, Atopic / drug therapy*
  • Dinitrochlorobenzene / toxicity
  • Disease Models, Animal
  • Immunoglobulin E / blood
  • Interleukin-4 / blood
  • Mice
  • Plant Extracts / therapeutic use*
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Dinitrochlorobenzene
  • Plant Extracts
  • Tumor Necrosis Factor-alpha
  • Interleukin-4
  • Immunoglobulin E